Latest filings (excl ownership)
15-12G
Securities registration termination
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Feb 23
8-K
Completion of Acquisition or Disposition of Assets
24 Feb 23
25-NSE
Exchange delisting
24 Feb 23
SC 14D9/A
Tender offer solicitation (amended)
24 Feb 23
SC TO-T/A
Third party tender offer statement (amended)
24 Feb 23
SC 14D9/A
Tender offer solicitation (amended)
23 Feb 23
SC TO-T/A
Third party tender offer statement (amended)
23 Feb 23
8-K
Regulation FD Disclosure
21 Feb 23
SC 14D9/A
Tender offer solicitation (amended)
15 Feb 23
SC 14D9/A
Tender offer solicitation (amended)
13 Feb 23
SC TO-T/A
Third party tender offer statement (amended)
3 Feb 23
SC 14D9/A
Tender offer solicitation (amended)
3 Feb 23
SC 14D9
Tender offer solicitation
23 Jan 23
SC TO-T
Third party tender offer statement
23 Jan 23
SC TO-C
Information about tender offer
9 Jan 23
8-K
CinCor Pharma to be Acquired by AstraZeneca
9 Jan 23
SC14D9C
Written communication relating to third party tender offer
9 Jan 23
8-K
Regulation FD Disclosure
28 Nov 22
8-K
Regulation FD Disclosure
8 Nov 22
8-K
CinCor Pharma Appoints Michael W. Kalb, Executive Vice President and Chief Financial Officer
7 Nov 22
8-K/A
Results of Operations and Financial Condition
4 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
CinCor Reports Third Quarter Financial Results and Provides Corporate Update
3 Nov 22
424B4
Prospectus supplement with pricing info
12 Aug 22
8-K
CinCor Pharma Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
11 Aug 22
EFFECT
Notice of effectiveness
11 Aug 22
POS EX
Additional exhibits for listing
10 Aug 22
S-1MEF
Registration of additional securities for an S-1
10 Aug 22
S-1
IPO registration
8 Aug 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
8-K
CinCor Reports Second Quarter Financial Results and Provides Corporate Update
8 Aug 22
8-K
Regulation FD Disclosure
8 Aug 22
CORRESP
Correspondence with SEC
8 Aug 22
CORRESP
Correspondence with SEC
8 Aug 22
UPLOAD
Letter from SEC
1 Aug 22
DRS
Draft registration statement
25 Jul 22
10-Q
2022 Q1
Quarterly report
10 May 22
8-K
CinCor Reports First Quarter Financial Results and Provides Corporate Update
10 May 22
10-K
2021 FY
Annual report
22 Mar 22
Latest ownership filings
SC 13D/A
Sofinnova Capital IX
3 Mar 23
SC 13D/A
Sofinnova Venture Partners X, L.P.
1 Mar 23
SC 13D/A
5AM Ventures VI, L.P.
28 Feb 23
4
Andrew J. Schwab
28 Feb 23
SC 13D/A
GENERAL ATLANTIC, L.P.
28 Feb 23
4
JAMES HEALY
27 Feb 23
4
Mason Freeman
27 Feb 23
4
David D. Allison
24 Feb 23
4
Troy A. Ignelzi
24 Feb 23
4
Michael Wayne Kalb
24 Feb 23
4
June Lee
24 Feb 23
4
Catherine Pearce
24 Feb 23
4
JOHN F THERO
24 Feb 23
4
Garidel Marc de
24 Feb 23
SC 13G
PERCEPTIVE ADVISORS LLC
14 Feb 23
SC 13D
Sofinnova Capital IX
13 Feb 23
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
9 Feb 23
4
Garidel Marc de
30 Jan 23
4
Catherine Pearce
30 Jan 23
4
Michael Wayne Kalb
30 Jan 23
4
Mason Freeman
30 Jan 23
4
Catherine Pearce
19 Jan 23
SC 13D
5AM Ventures VI, L.P.
18 Jan 23
SC 13D/A
GENERAL ATLANTIC, L.P.
11 Jan 23
4
David D. Allison
10 Jan 23
4
Michael Wayne Kalb
8 Nov 22
3
Michael Wayne Kalb
8 Nov 22
4
David D. Allison
12 Oct 22
SC 13G/A
venBio Global Strategic Fund III, L.P.
26 Sep 22
SC 13D/A
Sofinnova Venture Partners X, L.P.
22 Aug 22
4
Andrew J. Schwab
17 Aug 22
4
Partners SAS Sofinnova
17 Aug 22
4
Management X, L.L.C. Sofinnova
15 Aug 22
4
JAMES HEALY
15 Aug 22
4
Change in insider ownership
15 Aug 22
4
Atlantic Partners (Lux), SCSp General
15 Aug 22
4
JAMES HEALY
8 Aug 22
4
David D. Allison
20 Jul 22
4/A
David D. Allison
20 Jul 22
4
David D. Allison
11 May 22